The Mechanism of Action of Durvalumab in the Treatment of Urothelial Bladder Cancer

Video

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos